JP2008510770A5 - - Google Patents

Download PDF

Info

Publication number
JP2008510770A5
JP2008510770A5 JP2007528833A JP2007528833A JP2008510770A5 JP 2008510770 A5 JP2008510770 A5 JP 2008510770A5 JP 2007528833 A JP2007528833 A JP 2007528833A JP 2007528833 A JP2007528833 A JP 2007528833A JP 2008510770 A5 JP2008510770 A5 JP 2008510770A5
Authority
JP
Japan
Prior art keywords
halogen
sor
aryl
heterocyclyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007528833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008510770A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/054096 external-priority patent/WO2006021547A1/de
Publication of JP2008510770A publication Critical patent/JP2008510770A/ja
Publication of JP2008510770A5 publication Critical patent/JP2008510770A5/ja
Pending legal-status Critical Current

Links

JP2007528833A 2004-08-26 2005-08-19 Plk阻害剤としての新規プテリジノン Pending JP2008510770A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04020291 2004-08-26
PCT/EP2005/054096 WO2006021547A1 (de) 2004-08-26 2005-08-19 Pteridinone als plk (polo like kinase) inhibitoren

Publications (2)

Publication Number Publication Date
JP2008510770A JP2008510770A (ja) 2008-04-10
JP2008510770A5 true JP2008510770A5 (US07794700-20100914-C00152.png) 2008-10-09

Family

ID=34926314

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007528833A Pending JP2008510770A (ja) 2004-08-26 2005-08-19 Plk阻害剤としての新規プテリジノン

Country Status (5)

Country Link
US (1) US20060047118A1 (US07794700-20100914-C00152.png)
EP (1) EP1786817A1 (US07794700-20100914-C00152.png)
JP (1) JP2008510770A (US07794700-20100914-C00152.png)
CA (1) CA2575804A1 (US07794700-20100914-C00152.png)
WO (1) WO2006021547A1 (US07794700-20100914-C00152.png)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
KR20080002865A (ko) * 2005-03-25 2008-01-04 글락소 그룹 리미티드 피리도[2,3-d]피리미딘-7-온 및3,4-디히드로피리미도[4,5-d]피리미딘-2(1h)-온유도체의 제조 방법
CN101395155A (zh) * 2005-10-07 2009-03-25 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8247408B2 (en) 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
MEP8009A (en) 2006-09-15 2011-12-20 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
JP2010505962A (ja) * 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
GB0621203D0 (en) * 2006-10-25 2006-12-06 Chroma Therapeutics Ltd PLK inhibitors
EA200900593A1 (ru) * 2006-10-25 2010-06-30 Хрома Терапьютикс Лтд. Производные птеридина как ингибиторы polo-подобной киназы, применяющиеся при лечении рака
WO2009019205A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
US8889696B2 (en) 2009-12-18 2014-11-18 Temple University—Of the Commonwealth System of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
JP5841548B2 (ja) * 2010-02-17 2016-01-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法及び使用
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
ES2620521T3 (es) 2011-03-23 2017-06-28 Amgen Inc. Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
WO2013071217A1 (en) 2011-11-10 2013-05-16 OSI Pharmaceuticals, LLC Dihydropteridinones
US9670213B2 (en) 2012-05-14 2017-06-06 East China University Of Science And Technology Pteridine ketone derivative and applications thereof as EGFR, BLK, and FLT3 inhibitor
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
JP6631616B2 (ja) 2014-07-26 2020-01-15 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド CDK阻害剤としての2−アミノ−ピリド[2,3−d]ピリミジン−7(8H)−オン誘導体及びその使用
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
WO2017058831A1 (en) * 2015-10-01 2017-04-06 Boehringer Ingelheim International Gmbh Pteridine derivatives as modulators of ror gamma
CN106892922B (zh) * 2015-12-18 2019-04-19 华东理工大学 作为egfr抑制剂的5,8-二氢蝶啶-6,7-二酮衍生物及其应用
CN108721298A (zh) * 2017-04-19 2018-11-02 华东理工大学 作为布鲁顿酪氨酸激酶抑制剂的嘧啶并杂环化合物及其应用
US11773096B2 (en) 2018-08-10 2023-10-03 Yale University Small-molecule PI5P4K alpha/beta inhibitors and methods of treatment using same
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
MX2021012491A (es) * 2019-04-19 2022-01-24 Pfizer Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
AR119765A1 (es) 2019-08-14 2022-01-12 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
MX2022004390A (es) 2019-10-11 2022-08-08 Incyte Corp Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
CN113801118A (zh) * 2020-06-12 2021-12-17 华东理工大学 作为rsk抑制剂的蝶啶酮衍生物及其应用
JP2024508901A (ja) * 2021-03-08 2024-02-28 曁南大学 ピリドピリミジン系化合物及びその使用
CN113087708A (zh) * 2021-04-06 2021-07-09 南方医科大学 一种蝶啶酮类化合物及其应用
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
HUP0202713A3 (en) * 1999-09-15 2005-02-28 Warner Lambert Co Pteridinones as kinase inhibitors
BR0017075A (pt) * 2000-01-27 2002-11-05 Warner Lambert Co Derivados de piridopirimidinona para tratamento de doença neurodegenerativa
WO2001070741A1 (en) * 2000-03-06 2001-09-27 Warner-Lambert Company 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2008510770A5 (US07794700-20100914-C00152.png)
JP2008506644A5 (US07794700-20100914-C00152.png)
JP2014503574A5 (US07794700-20100914-C00152.png)
RU2395500C2 (ru) 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
JP2008508287A5 (US07794700-20100914-C00152.png)
JP2010511721A5 (US07794700-20100914-C00152.png)
JP2009504764A5 (US07794700-20100914-C00152.png)
JP2008503515A5 (US07794700-20100914-C00152.png)
JP2017504576A5 (US07794700-20100914-C00152.png)
JP2014500870A5 (US07794700-20100914-C00152.png)
JP2013540755A5 (US07794700-20100914-C00152.png)
JP2017506666A5 (US07794700-20100914-C00152.png)
JP2018517686A5 (US07794700-20100914-C00152.png)
JP2019524883A5 (US07794700-20100914-C00152.png)
JP2013537203A5 (US07794700-20100914-C00152.png)
JP2010540556A5 (US07794700-20100914-C00152.png)
JP2008533191A5 (US07794700-20100914-C00152.png)
JP2008510691A5 (US07794700-20100914-C00152.png)
JP2011509309A5 (US07794700-20100914-C00152.png)
JP2016515561A5 (US07794700-20100914-C00152.png)
JP2013510120A5 (US07794700-20100914-C00152.png)
JP2009529540A5 (US07794700-20100914-C00152.png)
JP2014511891A5 (US07794700-20100914-C00152.png)
JP2014500861A5 (US07794700-20100914-C00152.png)
JP2008501000A5 (US07794700-20100914-C00152.png)